Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026

Highlights include pooled safety findings from Paratek's Phase 3 studies in community acquired pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI), as well as additional clinical and non-clinical data from Company- and investigator-sponsored studies KING OF PRUSSIA, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on high-need, targeted therapeutic areas, today announced that new data from scientific and investigator-initiated studies of NUZYRA® (omadacycline) will be presented at ESCMID Global 2026, the annual Congress of the European Society of Clinical Microbiology and Infectious Diseases, taking place in Munich, Germany, April 17-21.